DreamCIS Report issue

For profit Phase 1
Founded: Seoul Korea, Republic of (2000)
Status: Acquired by Tigermed Consulting Co., Ltd (2015)

Organization Overview

First Clinical Trial
2019
NCT03855696
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Dream CIS, Inc.

Active Ingredients

Drugs in Phase 1 Trials (1)

mg1113 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hemophilia A (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1